Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its pipeline programs at the 2010 AACR (American Association for Cancer Research) annual meeting in Washington, DC. “We are pleased to present new data from our novel pipeline programs. Our Customized PEG linkers continue to improve the delivery of cytotoxic molecules,” said Dr. Ivan Horak, President of Research and Development and Chief Scientific Officer of Enzon. “Additionally, our novel locked nucleic acid (LNA)-based mRNA antagonists continue to show promise for inhibition of tumor growth in a variety of cancers.” The Posters and Abstracts that were presented included: Customized PEG Linkers Improve the Pharmaceutical Properties of Cytotoxic Small Molecules (Poster 2645) A series of releasable customized PEG linkers have been developed to improve the delivery of cytotoxic molecules. PEG-conjugates were synthesized with improved solubility and in general, increased the exposure time of the parent molecule.